Medication cost of persons with dementia in primary care in Germany
BACKGROUND: Results of cost-of-illness studies in dementia have shown a considerable divergence in costs of medication for persons with dementia. However, detailed economic analyses of medication costs for community-dwelling persons with dementia are currently still missing, especially on the basis of primary data.
OBJECTIVE: To determine medication cost, cost per drug, and number of drugs taken of community-dwelling persons with dementia and analyze their associated factors; to estimate the current price reduction of anti-dementia drugs due to implementation of low-priced generics.
METHOD: The present analysis included 205 patients screened positive for dementia. Medication data were assessed within a medication review. To estimate the cost effect of implementing generics, the most favorable equivalent generic was assigned to each anti-dementia drug. Factors associated with medication cost, cost per drug, and number of drugs taken were evaluated using multiple regression models.
RESULTS: Medication cost and cost per drug were higher and the number of taken drugs lower in advanced stages of cognitive impairment. Prescription of anti-dementia generics could decrease overall medication cost by 28%. Medication cost was associated with number of diagnoses, deficits in activities of daily living, and age. Dementia severity was related to cost per drug and number of drugs taken.
CONCLUSION: Medication cost increases with the number of diagnoses and growing deficits in activities of daily living and decreases with age. Severely cognitively impaired persons are treated with a small number of high-priced drugs, which could suggest inadequate medication of multimorbid persons.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Journal of Alzheimer's disease : JAD - 42(2014), 3 vom: 14., Seite 949-58 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Michalowsky, Bernhard [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antipsychotic Agents |
|---|
| Anmerkungen: |
Date Completed 25.08.2015 Date Revised 17.09.2014 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3233/JAD-140804 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM240999096 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM240999096 | ||
| 003 | DE-627 | ||
| 005 | 20231224123311.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3233/JAD-140804 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0803.xml |
| 035 | |a (DE-627)NLM240999096 | ||
| 035 | |a (NLM)25125471 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Michalowsky, Bernhard |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Medication cost of persons with dementia in primary care in Germany |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.08.2015 | ||
| 500 | |a Date Revised 17.09.2014 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Results of cost-of-illness studies in dementia have shown a considerable divergence in costs of medication for persons with dementia. However, detailed economic analyses of medication costs for community-dwelling persons with dementia are currently still missing, especially on the basis of primary data | ||
| 520 | |a OBJECTIVE: To determine medication cost, cost per drug, and number of drugs taken of community-dwelling persons with dementia and analyze their associated factors; to estimate the current price reduction of anti-dementia drugs due to implementation of low-priced generics | ||
| 520 | |a METHOD: The present analysis included 205 patients screened positive for dementia. Medication data were assessed within a medication review. To estimate the cost effect of implementing generics, the most favorable equivalent generic was assigned to each anti-dementia drug. Factors associated with medication cost, cost per drug, and number of drugs taken were evaluated using multiple regression models | ||
| 520 | |a RESULTS: Medication cost and cost per drug were higher and the number of taken drugs lower in advanced stages of cognitive impairment. Prescription of anti-dementia generics could decrease overall medication cost by 28%. Medication cost was associated with number of diagnoses, deficits in activities of daily living, and age. Dementia severity was related to cost per drug and number of drugs taken | ||
| 520 | |a CONCLUSION: Medication cost increases with the number of diagnoses and growing deficits in activities of daily living and decreases with age. Severely cognitively impaired persons are treated with a small number of high-priced drugs, which could suggest inadequate medication of multimorbid persons | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Dementia | |
| 650 | 4 | |a drug substitution | |
| 650 | 4 | |a drug therapy | |
| 650 | 4 | |a economics | |
| 650 | 4 | |a pharmaceutical economics | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 700 | 1 | |a Eichler, Tilly |e verfasserin |4 aut | |
| 700 | 1 | |a Thyrian, Jochen René |e verfasserin |4 aut | |
| 700 | 1 | |a Hertel, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Wucherer, Diana |e verfasserin |4 aut | |
| 700 | 1 | |a Laufs, Sebastian |e verfasserin |4 aut | |
| 700 | 1 | |a Fleßa, Steffen |e verfasserin |4 aut | |
| 700 | 1 | |a Hoffmann, Wolfgang |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of Alzheimer's disease : JAD |d 1998 |g 42(2014), 3 vom: 14., Seite 949-58 |w (DE-627)NLM097527327 |x 1875-8908 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2014 |g number:3 |g day:14 |g pages:949-58 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3233/JAD-140804 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2014 |e 3 |b 14 |h 949-58 | ||